Medytox Establishes U.S. Subsidiary to Expand BTX Market’s Global Reach

Meditox, a Korean botulinum toxin (BTX) manufacturer, said it has established a U.S. subsidiary, Luvantas, to enter the global market with its non-animal-derived liquid BTX preparation MT10109L.

The company submitted a Biologics License Application (BLA) for MT10109L to the FDA at the end of December.

The independently developed MT10109L eliminates animal-derived ingredients in the entire manufacturing process, including bacterial culture and raw material production, and does not use human serum albumin (HSA) as an adjuvant, fundamentally eliminating the possibility of animal-derived virus infection.

Luvantas, wholly owned by Medytox and headquartered in Irvine, California, will be responsible for local sales and marketing of MT10109L in the United States and Canada. In the future, the company will also be responsible for the market entry of advanced products such as the hyaluronic acid filler Neuramis and the dermocosmetic Neuraderm.

The company has named former Allergan executive Thomas Albright as Luvantas' first CEO. Albright is known for successfully leading the global launch of Botox for cosmetic purposes and overseeing its global marketing strategy.

Medytox is optimistic that Albright's expertise in the global cosmetic skin treatment market will lead to the successful launch of MT10109L in the U.S., with the drug targeting FDA approval in 2025.

The relevant person in charge of Medytox said: "The establishment of Luvantas marks that the company has been preparing for a long time to move towards a global biopharmaceutical company. We have completed the strategic planning and entered the actual execution stage. We will focus all our capabilities to obtain FDA approval for MT10109L and prepare for the successful entry into the United States."